Kenvue Inc. (NYSE:KVUE) Receives $19.58 Consensus Target Price from Analysts

Kenvue Inc. (NYSE:KVUE) has been assigned an average rating of “Hold” from the sixteen ratings firms that are presently covering the company, Marketbeat Ratings reports. Thirteen research analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $19.5833.

Several equities analysts have issued reports on KVUE shares. Jefferies Financial Group lowered Kenvue from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $23.00 to $18.00 in a report on Friday, January 30th. Canaccord Genuity Group boosted their target price on Kenvue from $17.00 to $18.00 and gave the company a “hold” rating in a report on Wednesday, February 18th. Barclays upped their target price on Kenvue from $18.00 to $19.00 and gave the company an “equal weight” rating in a research report on Friday, March 6th. Citigroup lifted their price target on Kenvue from $18.00 to $20.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 18th. Finally, UBS Group boosted their price objective on Kenvue from $17.00 to $19.00 and gave the company a “neutral” rating in a research note on Wednesday, February 18th.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of KVUE. Elyxium Wealth LLC acquired a new position in Kenvue in the 4th quarter valued at about $26,000. Physician Wealth Advisors Inc. lifted its position in Kenvue by 67.5% during the 4th quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock worth $26,000 after acquiring an additional 618 shares during the period. Cornerstone Planning Group LLC grew its stake in shares of Kenvue by 705.2% in the 3rd quarter. Cornerstone Planning Group LLC now owns 1,554 shares of the company’s stock valued at $25,000 after purchasing an additional 1,361 shares during the last quarter. NBT Bank N A NY grew its stake in shares of Kenvue by 180.3% in the 3rd quarter. NBT Bank N A NY now owns 1,564 shares of the company’s stock valued at $25,000 after purchasing an additional 1,006 shares during the last quarter. Finally, Salomon & Ludwin LLC acquired a new position in shares of Kenvue in the third quarter valued at approximately $25,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Kenvue Stock Performance

Shares of Kenvue stock opened at $17.57 on Friday. The company has a quick ratio of 0.68, a current ratio of 0.96 and a debt-to-equity ratio of 0.66. Kenvue has a 52 week low of $14.02 and a 52 week high of $25.17. The firm’s 50 day moving average is $18.01 and its two-hundred day moving average is $17.15. The firm has a market capitalization of $33.67 billion, a P/E ratio of 22.81, a P/E/G ratio of 4.01 and a beta of 0.51.

Kenvue (NYSE:KVUE) last issued its earnings results on Tuesday, February 17th. The company reported $0.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.22 by $0.05. Kenvue had a net margin of 9.72% and a return on equity of 19.72%. The business had revenue of $3.78 billion during the quarter, compared to analysts’ expectations of $3.68 billion. During the same quarter in the prior year, the business posted $0.26 EPS. The company’s revenue for the quarter was up 3.2% on a year-over-year basis. Research analysts forecast that Kenvue will post 1.14 EPS for the current fiscal year.

Kenvue Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, February 25th. Investors of record on Wednesday, February 11th were given a $0.2075 dividend. The ex-dividend date was Wednesday, February 11th. This represents a $0.83 annualized dividend and a yield of 4.7%. Kenvue’s dividend payout ratio is 107.79%.

About Kenvue

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.